Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00867126 · ClinicalTrials.gov registry record · Early Phase 1
Pioglitazone as Second-Line in Patients With Metastatic Pancreatic Cancer After Treatment With Gemcitabine
A Early Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT00867126: Clinical Trial Early Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
NCT00867126 is a Early Phase 1 study that was terminated before completion, run by University of Texas Southwestern Medical Center. The registered enrollment target is 6 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00867126, a Early Phase 1 study, was terminated before completion, sponsored by University of Texas Southwestern Medical Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
RATIONALE: Pioglitazone may slow the growth of tumor cells and may be an effective treatment for pancreatic cancer. PURPOSE: This phase I trial is studying how well pioglitazone works as second-line therapy in treating patients with metastatic pancreatic cancer that progressed after treatment with gemcitabine.
Interventions
- OTHER laboratory biomarker analysis
- OTHER questionnaire administration
- PROCEDURE quality-of-life assessment
- DRUG pioglitazone hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2009-03-02 |
| Est. Completion | 2012-02 |
| Phase | Early Phase 1 |
Why NCT00867126 stopped before completion
NCT00867126 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00867126 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00867126 about?
NCT00867126 is a clinical study titled "Pioglitazone as Second-Line in Patients With Metastatic Pancreatic Cancer After Treatment With Gemcitabine". RATIONALE: Pioglitazone may slow the growth of tumor cells and may be an effective treatment for pancreatic cancer. PURPOSE: This phase I trial is studying how well pioglitazone works as second-line therapy in treating patients with metastatic pancreatic cancer that progressed after treatment with ...
What is the current status of trial NCT00867126?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2009-03-02. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00867126?
The interventions under investigation include: laboratory biomarker analysis (OTHER), questionnaire administration (OTHER), quality-of-life assessment (PROCEDURE), pioglitazone hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00867126?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00867126's enrollment target sits among peer trials
6 1845th of 2000 higher than 114 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI